ID
34026
Beskrivning
Study ID: 101998 Clinical Study ID: 101998 Study Title: A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier Sponsor GlaxoSmithKline Collaborators N/A Phase Phase 3 Study Recruitment Status Completed Generic Name sumatriptan Trade Name Imitrex ,Imiject ,Imigran Study Indication Migraine Disorders This document asks if the subject is of child-bearing potential and which birth control methods the subject is using to prevent pregnancy during the study. This form should be filled out by female subjects at the screening visit.
Nyckelord
Versioner (3)
- 2019-01-11 2019-01-11 -
- 2019-01-13 2019-01-13 -
- 2019-01-17 2019-01-17 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
11 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Study Name: Efficacy and Tolerability of TREXIMA Tablets vs. Placebo During Mild Migraine Study ID 101998
Child Bearing Potential and Birth Control
- StudyEvent: ODM
Similar models
Child Bearing Potential and Birth Control
- StudyEvent: ODM
C0086129 (UMLS CUI [1,2])
C0004764 (UMLS CUI [1,2])
C0042241 (UMLS CUI [2])
C3873750 (UMLS CUI [3])
C2348235 (UMLS CUI [1,2])